More Encouraging Data For Moderna And Merck & Co’s Personalized Cancer Therapy

A therapy individualized to each patient’s cancer has produced encouraging three-year data – though talk of accelerated approval remains a moot point.

Confidence in Moderna and Merck & Co.'s novel individualized neoantigen therapy (INT) combination with Keytruda has grown after the companies unveiled new three-year data in melanoma patients.

The candidate mRNA-4157 (V940) is a potential first-in-class INT which is important for Merck as it looks to extend its dominance in cancer immunotherapy and vital for Moderna as it...

Key Takeaways

Moderna and Merck believe they can be first with a neoantigen-based cancer immunotherapy
The updated Phase II...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Merus Bispecific Impresses In Head And Neck Cancer

23 May 2025

• By Andrew McConaghie

Updated Phase II results from petosemtamab have impressed ahead of ASCO, outshining Keytruda monotherapy and its bispecific rival from Bicara.

Zydus To Continue Mirabegron Sales, Looks To World-First Dual Shigella-Typhoid Vaccine

23 May 2025

• By Vibha Ravi

Zydus expects strong mirabegron sales in FY26 amid US litigation even as it builds a growth pillar in vaccines with a world-first, Gates Foundation-aided dual shigella-typhoid vaccine under development and others on the WHO prequalified list

Challenging Environment For Biopharma Is A Tailwind For Royalty Pharma

22 May 2025

• By Jessica Merrill

The royalty revenue stream acquirer has around 40 products in its portfolio and expects to generate roughly $3bn this year. Head of R&D and investments Marshall Urist talked about the investment strategy at the RBC Healthcare Conference.